Christian Zwingelstein


Christian has over 25 years’ experience in clinical development, with a focus on infectious and rare diseases (Roche, Chiron, Polyphor). While at Chiron, he participated in the development of inhaled tobramycin (solution and powder). He then joined Actelion, running Phase 1 and PoC studies. At Polyphor, Christian was responsible for the clinical development of murepavadin program and the First in Human study of its inhaled formulation. He has had numerous interactions with EMA and FDA regulatory authorities. Christian obtained his PharmD from the University of Strasbourg. At Antabio, Christian is in charge of design and implementation of the Phase 1 clinical program for ANT3310.